(Photo courtesy of San Francisco AIDS Foundation, featuring volunteer models.)

On December 16, 2025, ICAP presented the Grand Rounds — Doxycycline post-exposure prophylaxis for bacterial STIs and its impact on antimicrobial resistance.

 Doxycycline post-exposure prophylaxis (Doxy PEP) is a new tool to prevent sexually transmitted infections (STIs). This talk by Jean-Michel Molina, MD, PhD, professor of Medicine at the University of Paris Cité and head of the Infectious Diseases Department at the Saint-Louis and Lariboisière Hospitals in Paris, covered the evidence supporting the use of DoxyPEP to prevent syphilis and chlamydia infection in men who have sex with men and transgender women exposed to a high risk of STIs.The effect of DoxyPEP on gonorrhea and M. genitalium infections was also addressed as well as its impact on antimicrobial resistance (AMR) for both pathogens and other bystander bacteria. Data on women was also presented.

Jean-Michel Molina is professor of Medicine at the University of Paris Cité and head of the Infectious Diseases Department at the Saint-Louis and Lariboisière Hospitals in Paris. He has been involved in studies assessing new drugs and strategies for the treatment of HIV and has chaired the ANRS clinical trial group for the past 12 years. His department follows a cohort of more than 6,000 people living with HIV. He is also member of the INSERM research team U1342 investigating cell biology of viral infections at the Saint-Louis research institute. Since 2018, he has been involved in the prevention of HIV and STIs and led the ANRS IPERGAY PrEP trial in men who have sex with men, with his unit following more than 4,000 people on PrEP. Professor Molina has recently taken a new position as medical director of the Pasteur Institute in Paris with the task of fostering translational and clinical research in infectious diseases.